{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:09:28Z","timestamp":1782947368716,"version":"3.54.5"},"reference-count":188,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00702-020-02150-w","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T22:10:32Z","timestamp":1580249432000},"page":"131-147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate \u03b1-synuclein cytotoxicity in disease-modifying therapy for Parkinson\u2019s disease"],"prefix":"10.1007","volume":"127","author":[{"given":"Makoto","family":"Naoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wakako","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayo","family":"Shamoto-Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,28]]},"reference":[{"issue":"4","key":"2150_CR1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.1471-4159.2002.01047.x","volume":"82","author":"Y Akao","year":"2002","unstructured":"Akao Y, Maruyama W, Shimizu S, Yi H, Shamoto-Nagai M, Youdim MB, Tsujimoto Y, Naoi M (2002a) Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and its inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem 82(4):913\u2013923","journal-title":"J Neurochem"},{"issue":"2","key":"2150_CR2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0304-3940(02)00332-4","volume":"326","author":"Y Akao","year":"2002","unstructured":"Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M (2002b) An anti-Parkinson\u2019s disease drug, N-propargyl-1(R)-aminoindan (rasagiline) enhanced expression of anti-apoptotic bcl-2 in human dopaminergic SH-SYY cells. Neurosci Lett 326(2):105\u2013108","journal-title":"Neurosci Lett"},{"issue":"29","key":"2150_CR3","doi-asserted-by":"crossref","first-page":"10580","DOI":"10.1073\/pnas.1401591111","volume":"111","author":"KN Alavian","year":"2014","unstructured":"Alavian KN, Beutner G, Lazrove E et al (2014) An uncoupling channel within the c-subunit ring of the F1F0 ATP synthase is the mitochondrial permeability transition pore. Proc Natl Acad Sci USA 111(29):10580\u201310585","journal-title":"Proc Natl Acad Sci USA"},{"key":"2150_CR4","doi-asserted-by":"crossref","first-page":"1019442","DOI":"10.1016\/j.npep.2019.101942","volume":"77","author":"H Amini-Khoei","year":"2019","unstructured":"Amini-Khoei H, Saghaei E, Mobini GR, Sabzevary-Ghahfarokhi M, Ahmadi R, Baghaeri N, Mokhtari T (2019) Possible involvement of PI3K\/Akt\/mTOR signaling pathway in the protective effect of selegiline (deprenyl) against memory impairment following ischemic\/reperfusion in rat. Neuropeptides 77:1019442","journal-title":"Neuropeptides"},{"issue":"9","key":"2150_CR5","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1523\/JNEUROSCI.13-09-04042.1993","volume":"13","author":"KS Ansari","year":"1993","unstructured":"Ansari KS, Yu PH, Kruck TPA, Tatton WG (1993) Rescue of axotomized immature rat facial motoneurons by R(\u2212)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 13(9):4042\u20134053","journal-title":"J Neurosci"},{"issue":"12","key":"2150_CR6","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/archneurol.2009.247","volume":"66","author":"A Ascherio","year":"2009","unstructured":"Ascherio A, LeWitt PA, Xu K et al (2009) Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 66(12):1460\u20131468","journal-title":"Arch Neurol"},{"issue":"1","key":"2150_CR7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2014.226","volume":"11","author":"D Athauda","year":"2015","unstructured":"Athauda D, Foltynie T (2015) The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat Rev Neurol 11(1):25\u201340","journal-title":"Nat Rev Neurol"},{"key":"2150_CR8","doi-asserted-by":"crossref","unstructured":"Bajracharya R, Yougson NA, Ballard JWO (2019) Dietary macronutrient management to treat mitochondrial dysfunction in Parkinson\u2019s disease. Int J Mol Sci 20(8):1850.","DOI":"10.3390\/ijms20081850"},{"issue":"5","key":"2150_CR9","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1471-4159.2004.02425.x","volume":"89","author":"O Bar-Am","year":"2004","unstructured":"Bar-Am O, Yogev-Falach M, Amit T, Sagi Y, Youdim MB (2004a) Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J Neurochem 89(5):1119\u20131125","journal-title":"J Neurochem"},{"issue":"3","key":"2150_CR10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.neulet.2003.10.067","volume":"355","author":"O Bar-Am","year":"2004","unstructured":"Bar-Am O, Amit T, Youdim MBH (2004b) Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 355(3):169\u2013172","journal-title":"Neurosci Lett"},{"issue":"13","key":"2150_CR11","doi-asserted-by":"crossref","first-page":"18890","DOI":"10.1096\/fj.05-3794fje","volume":"19","author":"O Bar-Am","year":"2005","unstructured":"Bar-Am O, Weinreb O, Amit T, Youdim MBH (2005) Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J 19(13):18890\u201321901","journal-title":"FASEB J"},{"issue":"2","key":"2150_CR12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00702-015-1395-3","volume":"123","author":"O Bar-Am","year":"2016","unstructured":"Bar-Am O, Amit T, Youdim MB, Weinreb O (2016) Neuroprotective and neurorestrorative potential of propargylamine derivatives in aging: focus on mitochondrial targets. J Neural Transm 123(2):125\u2013135","journal-title":"J Neural Transm"},{"issue":"8","key":"2150_CR13","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/ene.12724","volume":"22","author":"P Barone","year":"2015","unstructured":"Barone P, Santangelo G, Morgante L et al (2015) A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson\u2019s disease patients. Eur J Neurol 22(8):1184\u20131191","journal-title":"Eur J Neurol"},{"issue":"4","key":"2150_CR14","doi-asserted-by":"crossref","first-page":"e62277","DOI":"10.1371\/journal.pone.0062277","volume":"8","author":"A Bender","year":"2013","unstructured":"Bender A, Desplats P, Spencer B et al (2013) TOM40 mediates mitochondrial dysfunction induced by \u03b1-synuclein accumulation in Parkinson\u2019s disease. PLoS ONE 8(4):e62277","journal-title":"PLoS ONE"},{"issue":"2","key":"2150_CR15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.tips.2006.12.005","volume":"28","author":"MM Bespalov","year":"2007","unstructured":"Bespalov MM, Saarma M (2007) GDNF family receptor complexes are emerging drug targets. Trends Pharmacol Sci 28(2):68\u201374","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"2150_CR16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF01245973","volume":"64","author":"W Birkmayer","year":"1985","unstructured":"Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of \u029f-deprenyl to Madopar treatment in Parkinson\u2019s disease; a long term study. J Neural Transm 64(4):113\u2013127","journal-title":"J Neural Transm"},{"issue":"8","key":"2150_CR17","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00702-004-0123-1","volume":"111","author":"F Blandini","year":"2004","unstructured":"Blandini F, Cosentino M, Mangiagalli A et al (2004) Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson\u2019s disease. The effect of dopaminergic treatment. J Neural Transm 111(8):1017\u20131030","journal-title":"J Neural Transm"},{"issue":"8","key":"2150_CR18","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.3390\/nu11081896","volume":"11","author":"C Boulos","year":"2019","unstructured":"Boulos C, Yaghi N, Hayeck R, Heraoui G, Fakhouty-Sayegh N (2019) Nutritional risk factors, microbiota and Parkinson\u2019s disease: what is the current evidence? Nutrients 11(8):1896","journal-title":"Nutrients"},{"key":"2150_CR19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neuroscience.2011.10.057","volume":"211","author":"J Bove","year":"2012","unstructured":"Bove J, Perier C (2012) Neurotoxin-based models of Parkinson\u2019s disease. Neuroscience 211:51\u201376","journal-title":"Neuroscience"},{"issue":"2","key":"2150_CR20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Tredici KD, R\u00fcb U, de Vos RAI, Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging 24(2):197\u2013211","journal-title":"Neurobiol Aging"},{"issue":"1","key":"2150_CR21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jmb.2010.10.027","volume":"405","author":"CA Braga","year":"2011","unstructured":"Braga CA, Follmer C, Palhano FL et al (2011) The anti-parkinsonian selegiline delays the nucleation phase of \u03b1-synuclein aggregation leading to the formation of nontoxic species. J Mol Biol 405(1):254\u2013273","journal-title":"J Mol Biol"},{"key":"2150_CR22","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1161\/CIRCRESAHA.112.265942","volume":"111","author":"C Brenner","year":"2012","unstructured":"Brenner C, Moulin M (2012) Physiological roles of the permeability transition pore. Circ Res 111:1222\u20131236","journal-title":"Circ Res"},{"issue":"PtB","key":"2150_CR23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.expneurol.2017.10.003","volume":"298","author":"P Brundin","year":"2017","unstructured":"Brundin P, Dave KD, Kordower JH (2017) Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol 298(PtB):225\u2013235","journal-title":"Exp Neurol"},{"issue":"2","key":"2150_CR24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.expneurol.2009.03.006","volume":"218","author":"H B\u00fceler","year":"2009","unstructured":"B\u00fceler H (2009) Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson\u2019s disease. Exp Neurol 218(2):235\u2013246","journal-title":"Exp Neurol"},{"issue":"2","key":"2150_CR25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00401-007-0303-9","volume":"115","author":"WJ Burke","year":"2008","unstructured":"Burke WJ, Kumar VB, Pandey N et al (2008) Aggregation of \u03b1-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol 115(2):193\u2013203","journal-title":"Acta Neuropathol"},{"issue":"25","key":"2150_CR26","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/0024-3205(92)90528-W","volume":"50","author":"MC Carrillo","year":"1992","unstructured":"Carrillo MC, Kitani K, Kanai S, Sato Y, Ivy GO (1992) The ability of (\u2212)deprenyl to increase superoxide dismutase activities in he rat is tissue region selective. Life Sci 50(25):1985\u20131992","journal-title":"Life Sci"},{"issue":"8","key":"2150_CR27","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.febslet.2011.03.046","volume":"585","author":"M Caruana","year":"2011","unstructured":"Caruana M, H\u00f6gen T, Levin J, Hillmer A, Giese A, Vassallo N (2011) Inhibition and disaggregation of \u03b1-synuclein oligomers by natural polyphenolic compounds. FEBS Lett 585(8):1113\u20131120","journal-title":"FEBS Lett"},{"issue":"5","key":"2150_CR28","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.neuint.2010.06.017","volume":"57","author":"KY Chau","year":"2010","unstructured":"Chau KY, Cooper JM, Schapira AHV (2010) Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells. Neurochem Int 57(5):525\u2013529","journal-title":"Neurochem Int"},{"issue":"30","key":"2150_CR29","doi-asserted-by":"crossref","first-page":"27382","DOI":"10.1074\/jbc.M303808200","volume":"278","author":"C Chinopoulos","year":"2003","unstructured":"Chinopoulos C, Starkov AA, Fiskum G (2003) Cyclosporin A-insensitive permeability transition in brain mitochondria: inhibition by 2-aminoethoxydiphenyl borate. J Biol Chem 278(30):27382\u201327389","journal-title":"J Biol Chem"},{"issue":"3","key":"2150_CR30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.neulet.2010.09.061","volume":"486","author":"SJ Chinta","year":"2010","unstructured":"Chinta SJ, Mallajosyula JK, Rane A, Andersen JK (2010) Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett 486(3):235\u2013239","journal-title":"Neurosci Lett"},{"key":"2150_CR31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40478-015-0200-8","volume":"3","author":"C Ciron","year":"2015","unstructured":"Ciron C, Zheng L, Bobela W, Knott GW, Leone TC, Kelly DP, Schneide BL (2015) PGC-1\u03b1 activity in nigral dopamine neurons determined vulnerability to \u03b1-synuclein. Acta Neuropathol Commun 3:16","journal-title":"Acta Neuropathol Commun"},{"key":"2150_CR32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1471-2350-12-69","volume":"12","author":"J Clark","year":"2011","unstructured":"Clark J, Reddy S, Zheng K, Betensky RA, Simon DK (2011) Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson\u2019s disease. BMC Med Genet 12:69","journal-title":"BMC Med Genet"},{"key":"2150_CR33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.freeradbiomed.2016.06.023","volume":"100","author":"JC Corona","year":"2016","unstructured":"Corona JC, Duchen MR (2016) PPAR\u03b3 as a therapeutic target to rescue mitochondrial function in neurological disease. Free Radic Biol Med 100:153\u2013163","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"2150_CR34","doi-asserted-by":"crossref","first-page":"e9313","DOI":"10.1371\/journal.pone.0009313","volume":"5","author":"L Crews","year":"2010","unstructured":"Crews L, Spencer B, Desplats P et al (2010) Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of \u03b1-synucleinopathy. PLoS ONE 5(2):e9313","journal-title":"PLoS ONE"},{"issue":"6","key":"2150_CR35","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.22400","volume":"69","author":"V Cullen","year":"2011","unstructured":"Cullen V, Sardi SP, Ng J et al (2011) Acid-\u03b2-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter \u03b1-synuclein processing. Ann Neurol 69(6):940\u2013953","journal-title":"Ann Neurol"},{"issue":"3","key":"2150_CR36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.neuint.2005.09.006","volume":"48","author":"A Czerniczyniec","year":"2006","unstructured":"Czerniczyniec A, Bustamante J, Lores-Arnaiz S (2006) Modulation of brain mitochondrial function by deprenyl. Neurochem Int 48(3):235\u2013241","journal-title":"Neurochem Int"},{"key":"2150_CR37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fchem.2018.00181","volume":"6","author":"S Das","year":"2018","unstructured":"Das S, Pukala T, Smid SD (2018) Exploring the structural diversity in inhibitors of \u03b1-synuclein amyloidogenic folding, aggregation and neurotoxicity. Front Chem 6:181","journal-title":"Front Chem"},{"issue":"1","key":"2150_CR38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bbadis.2009.07.007","volume":"1802","author":"L Devi","year":"2010","unstructured":"Devi L, Anandatheerthavarada HK (2010) Mitochondrial trafficking of APP and alpha synuclein: relevance to mitochondrial dysfunction in Alzheimer\u2019s and Parkinson\u2019s diseases. Biochim Biophys Acta 1802(1):11\u201319","journal-title":"Biochim Biophys Acta"},{"key":"2150_CR39","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.freeradbiomed.2013.01.018","volume":"62","author":"DT Dexter","year":"2013","unstructured":"Dexter DT, Jenner P (2013) Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 62:132\u2013144","journal-title":"Free Radic Biol Med"},{"key":"2150_CR40","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2210-11-2","volume":"11","author":"W Dimpfel","year":"2011","unstructured":"Dimpfel W, Hoffmann JA (2011) Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in rat hippocampus slice in vitro. BMC Pharmacol 11:2","journal-title":"BMC Pharmacol"},{"issue":"4","key":"2150_CR41","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1211\/jpp.58.4.0016","volume":"58","author":"S Dragoni","year":"2006","unstructured":"Dragoni S, Porcari V, Travagli M, Castagnolo D, Valoti M (2006) Antioxidant properties of propargylamine derivatives: assessment of their ability to scavenge peroxynitrite. J Pharm Pharmacol 58(4):561\u2013565","journal-title":"J Pharm Pharmacol"},{"issue":"7","key":"2150_CR42","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/ene.13919","volume":"26","author":"R Durcan","year":"2019","unstructured":"Durcan R, Wiblin L, Lawson RA et al (2019) Prevalence and duration of non-motor symptoms in prodromal Parkinson\u2019s disease. Eur J Neurol 26(7):979\u2013985","journal-title":"Eur J Neurol"},{"key":"2150_CR43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1756-6606-4-43","volume":"4","author":"M Elstner","year":"2011","unstructured":"Elstner M, M\u00fcller SK, Leidolt L et al (2011) Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions. Mol Brain 4:43","journal-title":"Mol Brain"},{"issue":"S1","key":"2150_CR44","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1002\/ana.410320722","volume":"32","author":"S Fahn","year":"1992","unstructured":"Fahn S (1992) A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson\u2019s disease. Ann Neurol 32(S1):S128\u2013S132","journal-title":"Ann Neurol"},{"issue":"22","key":"2150_CR45","doi-asserted-by":"crossref","first-page":"11028","DOI":"10.1073\/pnas.1821332116","volume":"116","author":"SE Fanibunda","year":"2019","unstructured":"Fanibunda SE, Deb S, Maniyadath B et al (2019) Serotonin regulated mitochondrial biogenesis and function in rodent cortical neurons via the 5-HT2A receptor and SIRT1-PGC-1\u03b1 axis. Proc Nat Acad Sci USA 116(22):11028\u201311037","journal-title":"Proc Nat Acad Sci USA"},{"issue":"7","key":"2150_CR46","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.bbadis.2014.02.010","volume":"1842","author":"A Ferretta","year":"2014","unstructured":"Ferretta A, Gaballo A, Tanzarella P et al (2014) Effect of resveratrol on mitochondrial function: implications in parkin-associated familiar Parkinson\u2019s disease. Biochim Biophys Acta 1842(7):902\u2013915","journal-title":"Biochim Biophys Acta"},{"key":"2150_CR47","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3389\/fphar.2016.00340","volume":"7","author":"JP Finberg","year":"2016","unstructured":"Finberg JP, Rabey JM (2016) Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Front Pharmacol 7:350","journal-title":"Front Pharmacol"},{"key":"2150_CR48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nbd.2015.11.006","volume":"86","author":"S Fossati","year":"2016","unstructured":"Fossati S, Giannoni P, Solesio ME, Cocklin SL, Cabrera E, Ghiso J, Rostagno A (2016) The carbonic anhydrase inhibitor methazolamide prevents amyloid beta-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain. Neurobiol Dis 86:29\u201340","journal-title":"Neurobiol Dis"},{"issue":"8\u20139","key":"2150_CR49","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/BF01291788","volume":"103","author":"M Gerlach","year":"1996","unstructured":"Gerlach M, Riederer P (1996) Animal models of Parkinson\u2019s disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103(8\u20139):987\u20131041","journal-title":"J Neural Transm"},{"issue":"7","key":"2150_CR50","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.15252\/embr.201643354","volume":"18","author":"V Giorgio","year":"2017","unstructured":"Giorgio V, Burchell V, Schiavone M et al (2017) Ca2+ binding to F-ATP synthase \u03b2 subunit triggers the mitochondrial permeability transition. EMBO Rep 18(7):1065\u20131076","journal-title":"EMBO Rep"},{"key":"2150_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-019-02106-9","author":"DS Goldstein","year":"2019","unstructured":"Goldstein DS (2019) The catecholadehyde hypothesis: where MAO fits in. J Neural Transm. https:\/\/doi.org\/10.1007\/s00702-019-02106-9","journal-title":"J Neural Transm"},{"issue":"2","key":"2150_CR52","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s12640-015-9574-4","volume":"29","author":"S Golko-Perez","year":"2016","unstructured":"Golko-Perez S, Mandel S, Amit T, Kuperschmidt L, Youdim MB, Weinreb O (2016) Additive neuroprotective effects of the multifunctional iron chelator M30 with enriched diet in a mouse model of amyotrophic lateral sclerosis. Neurotox Res 29(2):208\u2013217","journal-title":"Neurotox Res"},{"issue":"11","key":"2150_CR53","doi-asserted-by":"crossref","first-page":"E2634","DOI":"10.1073\/pnas.1713849115","volume":"115","author":"D Grassi","year":"2018","unstructured":"Grassi D, Howarrd S, Zhou M et al (2018) Identification of a highly neurotoxic \u03b1-synuclein species inducing mitochondrial damage and mitophagy in Parkinson\u2019s disease. Proc Natl Acad Sci USA 115(11):E2634\u2013E2643","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2150_CR54","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/archneur.63.4.584","volume":"63","author":"S Greffard","year":"2006","unstructured":"Greffard S, Verny M, Bonnet AM et al (2006) Motor score of the United Parkinson Disease Rating Score as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 63(4):584\u2013588","journal-title":"Arch Neurol"},{"issue":"7","key":"2150_CR55","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1093\/nar\/gkn084","volume":"36","author":"J Gr\u00fcndemann","year":"2008","unstructured":"Gr\u00fcndemann J, Schlaudraff F, Haeckel O, Liss B (2008) Elevated \u03b1-synuclein mRNA levels in individual UV-lase-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson\u2019s disease. Nucleic Acids Res 36(7):e38","journal-title":"Nucleic Acids Res"},{"key":"2150_CR56","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pneurobio.2018.09.003","volume":"177","author":"A Gr\u00fcnewald","year":"2019","unstructured":"Gr\u00fcnewald A, Kumar KR, Sue CM (2019) New insights into the complex role of mitochondria in Parkinson\u2019s disease. Prog Neurobiol 177:73\u201393","journal-title":"Prog Neurobiol"},{"issue":"Pt 11","key":"2150_CR57","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1093\/brain\/awh584","volume":"128","author":"GM Halliday","year":"2005","unstructured":"Halliday GM, Ophof A, Broe M et al (2005) Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson\u2019s disease. Brain 128(Pt 11):2654\u20132684","journal-title":"Brain"},{"issue":"2","key":"2150_CR58","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1212\/WNL.58.2.308","volume":"58","author":"A Hartmann","year":"2002","unstructured":"Hartmann A, Mouatt-Prigent A, Faucheux BA, Agid Y, Hirsch EC (2002) FADD: a link between TNF family receptors and caspases in Parkinson\u2019s disease. Neurology 58(2):308\u2013310","journal-title":"Neurology"},{"issue":"2","key":"2150_CR59","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1006\/abbi.1996.0510","volume":"335","author":"N Hauptmann","year":"1996","unstructured":"Hauptmann N, Grimesby J, Shih JC, Cadenas E (1996) The metabolism of tyramine by monoamine oxidase A\/B causes oxidative damage to mitochondrial DNA. Arch Biochem Biophys 335(2):295\u2013304","journal-title":"Arch Biochem Biophys"},{"issue":"5985","key":"2150_CR60","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/311467a0","volume":"311","author":"RE Heikkila","year":"1984","unstructured":"Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine inhibitors. Nature 311(5985):467\u2013469","journal-title":"Nature"},{"issue":"4","key":"2150_CR61","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1021\/acschemneuro.7b00034","volume":"8","author":"A Herrera","year":"2017","unstructured":"Herrera A, Munoz P, Steinbusch HWM, Segura-Aguilar J (2017) Are dopamine oxidation metabolites involved in the loss of dopaminergic neurons in the nigrostriatal system in Parkinson\u2019s disease? ACS Chem Neurosci 8(4):702\u2013711","journal-title":"ACS Chem Neurosci"},{"issue":"3","key":"2150_CR62","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.molcel.2014.06.001","volume":"55","author":"E Hollville","year":"2014","unstructured":"Hollville E, Carroll RG, Cullen SP, Martin SJ (2014) Bcl-2 family proteins participate in mitochondrial quality control by regulating Parkin\/PINK-1-dependent mitophagy. Mol Cell 55(3):451\u2013466","journal-title":"Mol Cell"},{"issue":"2","key":"2150_CR63","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.20032053","volume":"200","author":"IG Stavrovskaya","year":"2004","unstructured":"Stavrovskaya IG, Maratanan MV, Zhang W et al (2004) Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. J Exp Med 200(2):211\u2013222","journal-title":"J Exp Med"},{"issue":"4","key":"2150_CR64","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00702-011-0730-6","volume":"119","author":"K Inaba-Hasegawa","year":"2012","unstructured":"Inaba-Hasegawa K, Akao Y, Maruyama W, Naoi M (2012) Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase. J Neural Transm 119(4):405\u2013414","journal-title":"J Neural Transm"},{"issue":"3","key":"2150_CR200","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00702-012-0899-3","volume":"120","author":"K Inaba-Hasegawa","year":"2013","unstructured":"Inaba-Hasegawa K, Akao Y, Maruyama W, Naoi M (2013) Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells. J Neural transm 120(3):435\u2013444","journal-title":"J Neural transm"},{"issue":"9","key":"2150_CR65","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00702-017-1740-9","volume":"124","author":"K Inaba-Hasegawa","year":"2017","unstructured":"Inaba-Hasegawa K, Shamoto-Nagai M, Maruyama W, Naoi M (2017) Type B and A monoamine oxidase and their inhibitors regulate the gene induction of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline. J Neural Transm 124(9):1055\u20131066","journal-title":"J Neural Transm"},{"issue":"7","key":"2150_CR66","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.bbadis.2008.07.006","volume":"1792","author":"KA Jellinger","year":"2009","unstructured":"Jellinger KA (2009) A critical evaluation of current stage of \u03b1-synuclein pathology in Lewy body disorders. Biochim Biophys Acta 1792(7):730\u2013740","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"2150_CR67","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.bbadis.2013.09.007","volume":"1842","author":"H Jin","year":"2014","unstructured":"Jin H, Kanthasamy A, Ghosh A, Anantharam V, Kalyanaraman B, Kanthasamy AG (2014) Mitochondria-targeted antioxidants for treatment of Parkinson\u2019s disease: preclinical and clinical outcomes. Biochim Biophys Acta 1842(8):1282\u20131294","journal-title":"Biochim Biophys Acta"},{"key":"2150_CR68","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.neulet.2015.01.064","volume":"590","author":"Y Jinsmaa","year":"2015","unstructured":"Jinsmaa Y, Cooney A, Sullivan P, Sharabi Y, Goldstein DS (2015) The serotonin aldehyde, 5-HIAL, oligomerized alpha-synuclein. Neurosci Lett 590:134\u2013137","journal-title":"Neurosci Lett"},{"issue":"2","key":"2150_CR69","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/jpet.119.262246","volume":"372","author":"Y Jinsmaa","year":"2020","unstructured":"Jinsmaa Y, Isonaka R, Sharabi Y, Goldstein DS (2020) 3,4-Dihydroxyphenylacetaldehyde is more efficient than dopamine in oligomerizing and quinonizing alpha-synuclein. J Pharmacol Exp Ther 372(2):157\u2013165","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2150_CR70","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.tins.2018.09.007","volume":"42","author":"ME Johnson","year":"2019","unstructured":"Johnson ME, Stecher B, Labrie V, Brundin L, Brundin P (2019) Triggers, facilitators, and aggregators: redefining Parkinson\u2019s disease pathogenesis. Trends Neurosci 42(1):4\u201313","journal-title":"Trends Neurosci"},{"issue":"2","key":"2150_CR71","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/cn5002914","volume":"6","author":"J Kakish","year":"2015","unstructured":"Kakish J, Tavassoly O, Lee JS (2015) Rasagiline, a suicide inhibitor of monoamine oxidase, binds reversibly to \u03b1-synuclein. ACS Chem Neurosci 6(2):347\u2013355","journal-title":"ACS Chem Neurosci"},{"issue":"9996","key":"2150_CR72","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 386(9996):896\u2013912","journal-title":"Lancet"},{"issue":"40","key":"2150_CR73","doi-asserted-by":"crossref","first-page":"10773","DOI":"10.1073\/pnas.1713969114","volume":"114","author":"SS Kang","year":"2017","unstructured":"Kang SS, Zhang Z, Liu X, Manfredsson FP, Benskey MJ, Cao X, Xu J, Sun YE, Ye K (2017) TrkB neurotrophic activities are blocked by \u03b1-synuclein and mediated pathological activities in Parkinson\u2019s disease. Proc Natl Acad Sci USA 114(40):10773\u201310778","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"2150_CR74","doi-asserted-by":"crossref","first-page":"e98878","DOI":"10.15252\/embj.201798878","volume":"37","author":"SS Kang","year":"2018","unstructured":"Kang SS, Ahn EH, Zhang Z et al (2018) \u03b1-Synuclein stimulation of monoamine oxidase-B and legmain protease mediates the pathology of Parkinson\u2019s disease. EMBO J 37(12):e98878","journal-title":"EMBO J"},{"issue":"6973","key":"2150_CR75","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature02229","volume":"427","author":"JE Kokoszka","year":"2004","unstructured":"Kokoszka JE, Waymire KG, Levy SE, Sligh JE, Cai J, Jones DP, MacGregor GR, Wallace DC (2004) The ADP\/ANT translocator is not essential for the mitochondrial permeability transition pore. Nature 427(6973):461\u2013465","journal-title":"Nature"},{"issue":"5","key":"2150_CR76","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/mds.27383","volume":"33","author":"JH Kordower","year":"2018","unstructured":"Kordower JH, Burke RE (2018) Disease modification for Parkinson\u2019s disease: axonal regeneration and trophic factors. Mov Disord 33(5):678\u2013683","journal-title":"Mov Disord"},{"issue":"45","key":"2150_CR77","doi-asserted-by":"crossref","first-page":"42802","DOI":"10.1074\/jbc.M207765200","volume":"277","author":"AJ Kowaltowski","year":"2002","unstructured":"Kowaltowski AJ, Gosso RG, Campos CB, Fiskum G (2002) Effect of Bcl-2 overexpression on mitochondrial structure and function. J Biol Chem 277(45):42802\u201342807","journal-title":"J Biol Chem"},{"key":"2150_CR78","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejphar.2018.12.027","volume":"845","author":"VB Kumar","year":"2019","unstructured":"Kumar VB, Hsu FF, Lakshmi VM, Gillespie KN, Burke WJ (2019) Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced \u03b1-synuclein aggregation and toxicity: implication for Parkinson neuroprotective therapy. Eur J Pharmacol 845:65\u201373","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"2150_CR79","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.chembiol.2018.08.005","volume":"25","author":"M Kurnik","year":"2018","unstructured":"Kurnik M, Sahin C, Andersen CB et al (2018) Potent \u03b1-synuclein aggregation inhibitors, identified by high-throughput screening, mainly target the monomeric state. Cell Chem Biol 25(11):1389\u20131402 (e9)","journal-title":"Cell Chem Biol"},{"issue":"5","key":"2150_CR80","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/mds.27360","volume":"33","author":"AE Lang","year":"2018","unstructured":"Lang AE, Espay AJ (2018) Disease modification in Parkinson\u2019s disease: current approaches, challenges, and future considerations. Mov Disord 33(5):660\u2013677","journal-title":"Mov Disord"},{"issue":"10","key":"2150_CR81","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/jnr.24042","volume":"95","author":"PA Li","year":"2017","unstructured":"Li PA, Hou X, Hao S (2017) Mitochondrial biogenesis in neurodegeneration. J Neurosci Res 95(10):2025\u20132029","journal-title":"J Neurosci Res"},{"issue":"2","key":"2150_CR82","doi-asserted-by":"crossref","first-page":"e4597","DOI":"10.1371\/journal.pone.0004597","volume":"4","author":"W Liu","year":"2009","unstructured":"Liu W, Vives-Bauza C, Acin-Perez R et al (2009) PINK-1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson\u2019s disease. PLoS ONE 4(2):e4597","journal-title":"PLoS ONE"},{"issue":"7","key":"2150_CR83","doi-asserted-by":"crossref","first-page":"E712","DOI":"10.3390\/cells8070712","volume":"8","author":"J Liu","year":"2019","unstructured":"Liu J, Kiu W, Li R, Yang H (2019) Mitophagy in Parkinson\u2019s disease: from pathogenesis to treatment. Cells 8(7):E712","journal-title":"Cells"},{"issue":"41","key":"2150_CR84","doi-asserted-by":"crossref","first-page":"10510","DOI":"10.1523\/JNEUROSCI.1659-16.2016","volume":"36","author":"MH Ludtmann","year":"2016","unstructured":"Ludtmann MH, Angelova PR, Ninkina NN, Gandhi S, Buchman VL, Abramov AY (2016) Monomeric alpha-synuclein exerts a physiological role on brain ATP synthase. J Neurosci 36(41):10510\u201310521","journal-title":"J Neurosci"},{"issue":"1","key":"2150_CR85","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1038\/s41467-018-04422-2","volume":"9","author":"MH Ludtmann","year":"2018","unstructured":"Ludtmann MH, Angelova PR, Horrocks MH et al (2018) \u03b1-Synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson\u2019s disease. Nat Commun 9(1):2293","journal-title":"Nat Commun"},{"issue":"12","key":"2150_CR86","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1007\/s11064-010-0238-8","volume":"35","author":"K Magyar","year":"2010","unstructured":"Magyar K, Szende B, Jenei V, Tabi T, Palfi M, Sz\u00f6ko E (2010) R-Deprenyl: pharmacological spectrum of its activity. Neurochem Res 35(12):1922\u20131932","journal-title":"Neurochem Res"},{"issue":"3","key":"2150_CR87","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/mds.27281","volume":"33","author":"P Mahlknecht","year":"2018","unstructured":"Mahlknecht P, Gasperi A, Djamshidian A et al (2018) Performance of the movement disorders society. Criteria for prodromal Parkinson\u2019s disease: a population-based 10-year study. Mov Disord 33(3):405\u2013413","journal-title":"Mov Disord"},{"issue":"10","key":"2150_CR88","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1007\/s11064-007-9351-8","volume":"32","author":"SA Mandel","year":"2007","unstructured":"Mandel SA, Sagi Y, Amit T (2007) Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway. Neurochem Res 32(10):1694\u20131699","journal-title":"Neurochem Res"},{"issue":"1","key":"2150_CR89","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00702-012-0876-x","volume":"120","author":"W Maruyama","year":"2013","unstructured":"Maruyama W, Naoi M (2013) \u201c70th Birthday Professor Riederer\u201d induction of glial cell-line-derived and brain-derived neurotrophic factors by rasagiline and (\u2212)deprenyl: a way to a disease-modifying therapy? J Neural Transm 120(1):83\u201389","journal-title":"J Neural Transm"},{"issue":"6","key":"2150_CR90","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1046\/j.1471-4159.1998.70062510.x","volume":"70","author":"W Maruyama","year":"1998","unstructured":"Maruyama W, Takahashi T, Naoi M (1998) (\u2212)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. J Neurochem 70(6):2510\u20132515","journal-title":"J Neurochem"},{"issue":"Suppl","key":"2150_CR91","first-page":"171","volume":"60","author":"W Maruyama","year":"2000","unstructured":"Maruyama W, Akao Y, Youdim MB, Naoi M (2000) Neurotoxins induce apoptosis in dopamine neurons: protection by N-propagylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J Neural Transm 60(Suppl):171\u2013186","journal-title":"J Neural Transm"},{"issue":"4","key":"2150_CR92","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1046\/j.1471-4159.2001.00448.x","volume":"78","author":"W Maruyama","year":"2001","unstructured":"Maruyama W, Akao Y, Youdim MB, Davis BA, Naoi M (2001a) Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem 78(4):727\u2013736","journal-title":"J Neurochem"},{"issue":"1","key":"2150_CR93","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s007020170093","volume":"108","author":"W Maruyama","year":"2001","unstructured":"Maruyama W, Boulton AA, Davis BA, Dostert P, Naoi M (2001b) Enantio-specific induction of apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine. J Neural Transm 108(1):11\u201324","journal-title":"J Neural Transm"},{"issue":"3","key":"2150_CR94","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0304-3940(03)00211-8","volume":"34","author":"W Maruyama","year":"2003","unstructured":"Maruyama W, Weinstock W, Youdim MB, Nagai M, Naoi M (2003) Antiapoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci Lett 34(3):233\u2013236","journal-title":"Neurosci Lett"},{"issue":"6","key":"2150_CR95","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.neuint.2003.08.005","volume":"44","author":"W Maruyama","year":"2004","unstructured":"Maruyama W, Nitta A, Shamoto-Nagai M, Hirata Y, Akao Y, Youdim M, Furukawa S, Nabeshima T, Naoi M (2004) N-Propargyl-1-(R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-\u03baB transcription factor. Neurochem Int 44(6):293\u2013400","journal-title":"Neurochem Int"},{"issue":"8","key":"2150_CR96","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/mds.27723","volume":"34","author":"C Milanese","year":"2019","unstructured":"Milanese C, Payan-Gomez C, Galvani M et al (2019) Peripheral mitochondrial function correlates with clinical severity in idiopathic Parkinson\u2019s disease. Mov Disord 34(8):1192\u20131202","journal-title":"Mov Disord"},{"key":"2150_CR97","doi-asserted-by":"crossref","first-page":"6405278","DOI":"10.1155\/2017\/6405278","volume":"2017","author":"LK Mischley","year":"2017","unstructured":"Mischley LK, Lau RC, Bennet RD (2017) Role of diet and nutritional supplements in Parkinson\u2019s disease progression. Oxid Med Cell Longev 2017:6405278","journal-title":"Oxid Med Cell Longev"},{"issue":"3","key":"2150_CR98","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/0006-291X(89)91141-8","volume":"163","author":"Y Mizuno","year":"1989","unstructured":"Mizuno Y, Ohta S, Tanaka M, Takakiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson\u2019s disease. Biochim Biophys Res Commun 163(3):1450\u20131455","journal-title":"Biochim Biophys Res Commun"},{"issue":"8","key":"2150_CR99","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1021\/cn500084x","volume":"5","author":"G Modi","year":"2014","unstructured":"Modi G, Voshavar C, Gigoi S, Shah M, Antonio T, Reith MEA, Dutta AK (2014) Multifunctional D2\/D3 agonist D-510 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregates. ACS Chem Neurosci 5(8):700\u2013717","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"2150_CR100","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.expneurol.2009.03.036","volume":"218","author":"S Morota","year":"2009","unstructured":"Morota S, Mansson R, Hansson MJ et al (2009) Evaluation of putative inhibitors of mitochondrial permeability transition for brain disorders\u2014specificity vs. toxicity. Exp Neurol 218(2):353\u2013362","journal-title":"Exp Neurol"},{"issue":"5","key":"2150_CR101","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00702-012-0927-3","volume":"120","author":"T M\u00fcller","year":"2013","unstructured":"M\u00fcller T, Hoffmann JA, Dimpfel W, Oehlwein C (2013) Switch from selegiline to rasagiline is beneficial in patients with Parkinson\u2019s disease. J Neural Transm 120(5):761\u2013765","journal-title":"J Neural Transm"},{"key":"2150_CR102","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0925-4439(96)00062-2","volume":"1360","author":"G M\u00fcnch","year":"1997","unstructured":"M\u00fcnch G, Mayer S, Michaelis J et al (1997) Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of \u03b2-amyloid peptide. Biochim Biophys Acta 1360:17\u201329","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"2150_CR103","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1212\/WNL.42.2.339","volume":"42","author":"VV Myllyl\u00e4","year":"1992","unstructured":"Myllyl\u00e4 VV, Sotaniemi KA, Vuorinen JA, Heionen EH (1992) Selegiline as initial treatment in de novo parkinsonian patients. Neurology 42(2):339\u2013343","journal-title":"Neurology"},{"issue":"3","key":"2150_CR104","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bbrc.2005.11.095","volume":"339","author":"K Nakaso","year":"2006","unstructured":"Nakaso K, Nakamura C, Sato H, Imamura K, Takeshima T, Nakashima K (2006) Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins. Biochem Biophys Res Commun 339(3):915\u2013922","journal-title":"Biochem Biophys Res Commun"},{"issue":"25","key":"2150_CR105","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.2174\/138161210793176527","volume":"16","author":"M Naoi","year":"2010","unstructured":"Naoi M, Maruyama W (2010) Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. Curr Pharm Des 16(25):2799\u20132817","journal-title":"Curr Pharm Des"},{"issue":"6","key":"2150_CR106","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1111\/j.1471-4159.2008.05329.x","volume":"105","author":"M Naoi","year":"2008","unstructured":"Naoi M, Maruyama W, Yi H et al (2008) Neuromelanin selectively induces apoptosis in dopaminergic SH-SY5Y cells by deglutathionylation in mitochondria: involvement of the protein and melanin component. J Neurochem 105(6):2489\u20132500","journal-title":"J Neurochem"},{"issue":"11","key":"2150_CR107","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00702-009-0309-7","volume":"115","author":"M Naoi","year":"2009","unstructured":"Naoi M, Maruyama W, Yi H, Inaba K, Akao Y, Shamoto-Nagai M (2009) Mitochondria in neurodegenerative disorders: regulation of the redox state and death signaling leading to neuronal death and survival. J Neural Transm 115(11):1371\u20131381","journal-title":"J Neural Transm"},{"issue":"6","key":"2150_CR108","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1586\/ern.13.60","volume":"13","author":"M Naoi","year":"2013","unstructured":"Naoi M, Maruyama W, Inaba-Hasegawa K (2013a) Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms. Expert Rev Neurother 13(6):671\u2013684","journal-title":"Expert Rev Neurother"},{"issue":"11","key":"2150_CR109","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00702-013-1033-x","volume":"120","author":"M Naoi","year":"2013","unstructured":"Naoi M, Maruyama W, Yi H (2013b) Rasagiline prevents apoptosis induced by PK11195, a ligand of the outer membrane translocator protein (18 kDa), in SH-SY5Y cells through suppression of cytochrome c release from mitochondria. J Neural Transm 120(11):1539\u20131551","journal-title":"J Neural Transm"},{"issue":"12","key":"2150_CR110","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s00702-017-1797-5","volume":"124","author":"M Naoi","year":"2017","unstructured":"Naoi M, Inaba-Hasegawa K, Shamoto-Nagai M, Maruyama W (2017) Neurotrophic function of phytochemicals for neuroprotection in aging and neurodegenerative disorders: modulation of intracellular signaling and gene expression. J Neural Transm 124(12):1515\u20131527","journal-title":"J Neural Transm"},{"issue":"11","key":"2150_CR111","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00702-017-1832-6","volume":"125","author":"M Naoi","year":"2018","unstructured":"Naoi M, Maruyama W, Shamoto-Nagai M (2018) Type A and B monoamine oxidases distinctly modulate signal transcription pathway and gene expression to regulate brain function and survival of neurons. J Neural Transm 125(11):1635\u20131650","journal-title":"J Neural Transm"},{"issue":"1","key":"2150_CR112","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/fnl-2018-0028","volume":"14","author":"M Naoi","year":"2019","unstructured":"Naoi M, Shamoto-Nagai M, Maruyama W (2019a) Neuroprotection of multifunctional phytochemicals as novel therapeutic strategy for neurodegenerative disorders: antiapoptotic and antiamyloidogenic activities by modulation of cellular signal pathways. Future Neurol 14(1):9","journal-title":"Future Neurol"},{"key":"2150_CR113","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.3390\/ijms20102451","volume":"20","author":"M Naoi","year":"2019","unstructured":"Naoi M, Wu Y, Shamoto-Nagai M, Maruyama W (2019b) Mitochondria in neuroprotection by phytochemicals: bioactive polyphenols modulate mitochondrial apoptosis system, function and structure. Int J Mol Sci 20:2451","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2150_CR114","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/embor.2009.256","volume":"11","author":"I Novak","year":"2010","unstructured":"Novak I, Kirkin V, McEwan DG et al (2010) Nix is a selective autophagy receptor for mitochondrial clearance. EMBO Rep 11(1):45\u201351","journal-title":"EMBO Rep"},{"key":"2150_CR115","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.3390\/ijms19113650","volume":"19","author":"T Numakawa","year":"2018","unstructured":"Numakawa T, Okada H, Adachi N (2018) Actions of brain-derived neurotrophin factor in the neurogenesis and neuronal function, and its involvement in the pathophysiology of brain diseases. Int J Mol Sci 19:3650","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2150_CR116","doi-asserted-by":"crossref","first-page":"e13726","DOI":"10.1111\/nmo.13726","volume":"32","author":"SM O\u2019Donovan","year":"2020","unstructured":"O\u2019Donovan SM, Crowley EK, Brown JR et al (2020) Nigral overexpression of \u03b1-synuclein in a rat Parkinson\u2019s disease model indicates alterations in the enteric nervous system and the gut microbiome. Neurogastroenterol Motil 32(1):e13726","journal-title":"Neurogastroenterol Motil"},{"issue":"15","key":"2150_CR117","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/mds.22218","volume":"23","author":"CW Olanow","year":"2008","unstructured":"Olanow CW, Hauser RA, Jankavic J et al (2008) A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson\u2019s disease (the ADAGIO): rationale, design, and baseline characteristics. Mov Disord 23(15):2194\u20132201","journal-title":"Mov Disord"},{"issue":"Pt. B","key":"2150_CR118","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.expneurol.2017.06.018","volume":"298","author":"CW Olanow","year":"2017","unstructured":"Olanow CW, Kieburtz K, Katz R (2017) Clinical approaches to the development of neuroprotective therapy for PD. Exp Neurol 298(Pt. B):246\u2013251","journal-title":"Exp Neurol"},{"issue":"7","key":"2150_CR119","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/jnr.21271","volume":"85","author":"K Ono","year":"2007","unstructured":"Ono K, Hirohata M, Yamada M (2007) Anti-fibrillogenic and fibril-destabilizing activities of anti-parkinsonian agents for \u03b1-synuclein fibrils in vitro. J Neurosci Res 85(7):1547\u20131557","journal-title":"J Neurosci Res"},{"issue":"10","key":"2150_CR120","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/jnr.23256","volume":"91","author":"K Ono","year":"2013","unstructured":"Ono K, Takasaki J, Takahashi R, Ikeda T, Yamada M (2013) Effects of antiparkinsonian agents on \u03b2-amyloid and \u03b1-synuclein oligomer formation in vitro. J Neurosci Res 91(10):1371\u20131381","journal-title":"J Neurosci Res"},{"issue":"8","key":"2150_CR121","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.bbadis.2010.12.022","volume":"1812","author":"C Pacelli","year":"2011","unstructured":"Pacelli C, De Rasmo D, Signorile A et al (2011) Mitochondrial defect and PGC-1\u03b1 dysfunction in parkin-associated familial Parkinson\u2019s disease. Biochim Biophys Acta 1812(8):1041\u20131053","journal-title":"Biochim Biophys Acta"},{"issue":"18","key":"2150_CR122","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1074\/jbc.M401135200","volume":"279","author":"JJ Palacino","year":"2004","unstructured":"Palacino JJ, Sagi D, Goldberg MS, Kraus S, Motz C, Wacker M, Klose J, Shen J (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279(18):14\u201322","journal-title":"J Biol Chem"},{"issue":"8","key":"2150_CR123","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1212\/01.wnl.0000204007.46190.54","volume":"66","author":"S Palhagen","year":"2006","unstructured":"Palhagen S, Heinonen E, H\u00e4gglund J et al (2006) Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66(8):1200\u20131206","journal-title":"Neurology"},{"issue":"10","key":"2150_CR124","first-page":"1052","volume":"46","author":"Parkinson Study Group","year":"1989","unstructured":"Parkinson Study Group (1989) DATATOP: a multicenter controlled clinical trial in early Parkinson\u2019s disease. Neurology 46(10):1052\u20131060","journal-title":"Neurology"},{"issue":"4","key":"2150_CR125","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archneur.61.4.561","volume":"61","author":"Parkinson Study Group","year":"2004","unstructured":"Parkinson Study Group (2004) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61(4):561\u2013566","journal-title":"Arch Neurol"},{"issue":"41","key":"2150_CR126","doi-asserted-by":"crossref","first-page":"10481","DOI":"10.1073\/pnas.1804198115","volume":"115","author":"J Pujols","year":"2018","unstructured":"Pujols J, Pena-Diaz S, Lazaro DF et al (2018) Small molecule inhibits \u03b1-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons. Proc Natl Acad Sci USA 115(41):10481\u201310486","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2150_CR127","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/ejn.14269","volume":"49","author":"RN Rees","year":"2019","unstructured":"Rees RN, Noyce AJ, Schrag A (2019) The prodromes of Parkinson\u2019s disease. Eur J Neurosci 49(3):320\u2013327","journal-title":"Eur J Neurosci"},{"key":"2150_CR128","doi-asserted-by":"crossref","first-page":"e1820","DOI":"10.1038\/cddis.2015.166","volume":"6","author":"AK Reeve","year":"2015","unstructured":"Reeve AK, Ludmann MHR, Angelova PR et al (2015) Aggregated \u03b1-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons. Cell Death Dis 6:e1820","journal-title":"Cell Death Dis"},{"issue":"4","key":"2150_CR129","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s13311-017-0544-9","volume":"14","author":"F Richter","year":"2017","unstructured":"Richter F, Subrammanian SR, Magen I et al (2017) A molecular tweezer ameliorates motor deficits in mice overexpressing \u03b1-synuclein. Neurotherapeutics 14(4):1107\u20131119","journal-title":"Neurotherapeutics"},{"issue":"11","key":"2150_CR130","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s00702-018-1876-2","volume":"125","author":"P Riederer","year":"2018","unstructured":"Riederer P, M\u00fcller T (2018) Monoamine oxidase-B inhibitors in the treatment of Parkinson\u2019s disease: clinical-pharmacological aspects. J Neural Transm 125(11):1751\u20131757","journal-title":"J Neural Transm"},{"issue":"7","key":"2150_CR131","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00702-019-02025-9","volume":"126","author":"P Riederer","year":"2019","unstructured":"Riederer P, Berg D, Casadel N et al (2019) \u03b1-Synuclein in Parkinson\u2019s disease: causal or bystander? J Neural Transm 126(7):815\u2013840","journal-title":"J Neural Transm"},{"issue":"3","key":"2150_CR132","first-page":"15","volume":"40","author":"DS Robinson","year":"2007","unstructured":"Robinson DS, Gillmor ML, Yang Y, Moonsammy G, Azzaro AJ, Oren DA, Campbel BJ (2007) Treatment effects of selegiline transdermal system on symptoms of major depressive disorders: a meta-analysis of short-term, placebo-controlled, efficacy trials. Psychopharmacol Bull 40(3):15\u201328","journal-title":"Psychopharmacol Bull"},{"issue":"30","key":"2150_CR133","doi-asserted-by":"crossref","first-page":"18467","DOI":"10.1074\/jbc.M115.641746","volume":"290","author":"T Rostovtseva","year":"2015","unstructured":"Rostovtseva T, Gurnev P, Protchenko O, Hoogerheide DP, Yap TL, Philpott CC, Lee JC, Bezrukov SM (2015) \u03b1-Synuclein shows high affinity interaction with voltage-dependent anion channel, suggesting mechanisms of mitochondrial regulation and toxicity in Parkinson disease. J Biol Chem 290(30):18467\u201318477","journal-title":"J Biol Chem"},{"issue":"6","key":"2150_CR134","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","volume":"167","author":"TR Sampson","year":"2016","unstructured":"Sampson TR, Debelius JW, Thron T et al (2016) Gut microbiota regulate motor deficits and neuroinflammation in a model of a model of Parkinson\u2019s disease. Cell 167(6):1469\u20131480","journal-title":"Cell"},{"issue":"1","key":"2150_CR135","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.neuint.2005.12.016","volume":"49","author":"KS Saravanan","year":"2006","unstructured":"Saravanan KS, Sindhu KM, Senthikumar KS, Mohanakumar KP (2006) \u029f-Deprenyl protects against rotenone-induced oxidative stress-mediated dopaminergic neurodegeneration in rats. Neurochem Int 49(1):28\u201340","journal-title":"Neurochem Int"},{"issue":"8","key":"2150_CR136","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1474-4422(13)70117-0","volume":"12","author":"AH Schapira","year":"2013","unstructured":"Schapira AH, McDermott MP, Barone P et al (2013) Pramipexole in patients with Parkinson\u2019s disease (PROUD): a randomised delayed-start trial. Lancet Neurol 12(8):747\u2013755","journal-title":"Lancet Neurol"},{"issue":"3","key":"2150_CR137","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/mds.26069","volume":"30","author":"F Scheperjans","year":"2015","unstructured":"Scheperjans F, Aho V, Pereira PA et al (2015) Gut microbiota are related to Parkinson\u2019s disease and clinical phenotype. Mov Disord 30(3):350\u2013358","journal-title":"Mov Disord"},{"issue":"1","key":"2150_CR138","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0014-2999(96)00593-6","volume":"315","author":"I Semkova","year":"1996","unstructured":"Semkova I, Wolz P, Schilling M, Krieglstein J (1996) Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. Eur J Pharmacol 315(1):19\u201330","journal-title":"Eur J Pharmacol"},{"issue":"13","key":"2150_CR139","first-page":"1826","volume":"16","author":"J Seo","year":"2002","unstructured":"Seo J, Rah J, Choi S et al (2002) \u03b1-Synuclein regulates neuronal survival via Bcl-2 family expression and PI3\/Akt kinase pathway. FASEB J 16(13):1826\u20131828","journal-title":"FASEB J"},{"issue":"5","key":"2150_CR140","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00702-005-0410-5","volume":"113","author":"M Shamoto-Nagai","year":"2006","unstructured":"Shamoto-Nagai M, Maruyama W, Yi H et al (2006) Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 20S proteasomes. J Neural Transm 113(5):633\u2013644","journal-title":"J Neural Transm"},{"issue":"12","key":"2150_CR141","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s00702-007-0789-2","volume":"114","author":"M Shamoto-Nagai","year":"2007","unstructured":"Shamoto-Nagai M, Maruyama W, Hashizume Y, Yoshida M, Osawa T, Riederer P, Naoi M (2007) In parkinsonian substantia nigra, \u03b1-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity. J Neural Transm 114(12):1559\u20131567","journal-title":"J Neural Transm"},{"issue":"6","key":"2150_CR142","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/mgg3.469","volume":"6","author":"Z Shanesazzade","year":"2018","unstructured":"Shanesazzade Z, Peymani M, Ghaedi K, Hossein M, Esfahani N (2018) miR-34a\/BL-2 signal axis contributes to apoptosis in MPP+-induced SH-SY5Y cells. Mol Genet Genom Med 6(6):975\u2013981","journal-title":"Mol Genet Genom Med"},{"key":"2150_CR143","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.brainres.2014.09.046","volume":"1591","author":"J Shen","year":"2014","unstructured":"Shen J, Du T, Wang X, Duan C, Gao G, Zhang J, Lu L, Yang H (2014) \u03b1-Synuclein amino terminus regulates mitochondrial membrane permeability. Brain Res 1591:14\u201326","journal-title":"Brain Res"},{"issue":"4","key":"2150_CR144","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.freeradbiomed.2012.05.024","volume":"53","author":"A Siddiqui","year":"2012","unstructured":"Siddiqui A, Chinta SJ, Mallajosyuka JK, Rajagopolan S, Hanson I, Rane A, Melov S, Anderson JK (2012) Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson\u2019s disease. Free Radic Biol Med 53(4):993\u20131003","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"2150_CR145","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/ejn.13869","volume":"49","author":"LM Smith","year":"2019","unstructured":"Smith LM, Parr-Brownie LC (2019) A neuroscience perspective of the gut theory of the gut therapy of Parkinson\u2019s disease. Eur J Neurosci 49(6):817\u2013823","journal-title":"Eur J Neurosci"},{"issue":"1","key":"2150_CR146","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4161\/auto.26751","volume":"10","author":"JX Song","year":"2014","unstructured":"Song JX, Lu JH, Liu LF, Chen LL, Durairajan SS, Yue Z, Zhang HQ, Li M (2014) HMGB1 is involved in autophagy inhibition caused by SNCA\/\u03b1-synuclein overexpression. Autophagy 10(1):144\u2013154","journal-title":"Autophagy"},{"issue":"8","key":"2150_CR147","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/hmg\/ddt600","volume":"23","author":"K Stafa","year":"2014","unstructured":"Stafa K, Tsika E, Moser R et al (2014) Functional interaction of Parkinson\u2019s disease-associated LRRK2 with members of the dynamin GPTase superfamily. Hum Mol Genet 23(8):2055\u20132077","journal-title":"Hum Mol Genet"},{"issue":"3","key":"2150_CR148","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3233\/JPD-160824","volume":"6","author":"NW Sterling","year":"2016","unstructured":"Sterling NW, Lewis MM, Du G, Huang X (2016) Structural imaging and Parkinson\u2019s disease: moving toward quantitative markers of disease progression. J Parkinsons Dis 6(3):557\u2013567","journal-title":"J Parkinsons Dis"},{"issue":"7","key":"2150_CR149","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archneur.64.7.nct60005","volume":"64","author":"A Storch","year":"2007","unstructured":"Storch A, Jost WH, Vieregge P et al (2007) Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol 64(7):938\u2013944","journal-title":"Arch Neurol"},{"issue":"5","key":"2150_CR150","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s12192-010-0177-y","volume":"15","author":"MV Subramanian","year":"2010","unstructured":"Subramanian MV, James TJ (2010) Age-related protective effect of deprenyl on changes in the levels of diagnostic marker enzymes and antioxidant defense enzymes activities in cerebellar tissue in Wistar rats. Cell Stress Chaperones 15(5):743\u2013751","journal-title":"Cell Stress Chaperones"},{"issue":"11","key":"2150_CR151","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00702-018-1853-9","volume":"125","author":"E Sz\u00f6ko","year":"2018","unstructured":"Sz\u00f6ko E, Tabi T, Riederer P, Vecsei L, Magyar K (2018) Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson\u2019s disease. J Neural Transm 125(11):1735\u20131749","journal-title":"J Neural Transm"},{"issue":"1","key":"2150_CR152","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0014-5793(95)00610-L","volume":"368","author":"F Sztark","year":"1995","unstructured":"Sztark F, Icjas F, Ouhabi R, Dabadie P, Mazal JP (1995) Effects of the anaesthetic propofol on the calcium-induced permeability transition of rat heart mitochondria: direct pore inhibition and shift of the gating potential. FEBS Lett 368(1):101\u2013104","journal-title":"FEBS Lett"},{"issue":"2","key":"2150_CR153","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/sj.emboj.7601972","volume":"27","author":"T Tatsuta","year":"2008","unstructured":"Tatsuta T, Langer T (2008) Quality control of mitochondria: protection against neurodegeneration and ageing. EMBO J 27(2):306\u2013314","journal-title":"EMBO J"},{"issue":"12","key":"2150_CR154","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1111\/febs.12817","volume":"281","author":"O Tavassoly","year":"2014","unstructured":"Tavassoly O, Nokhrin S, Dmitriev OY, Lee JS (2014) Cu(II) and dopamine bind to \u03b1-synuclein and cause large conformational changes. FEBS J 281(12):2738\u20132753","journal-title":"FEBS J"},{"issue":"4","key":"2150_CR155","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3390\/ijms20040901","volume":"20","author":"S Thellung","year":"2019","unstructured":"Thellung S, Corsaro A, Nizzari M, Barbieri F, Florio T (2019) Autophagy activator drugs: a new opportunity in neuroprotection from misfolded protein toxicity. Int J Mol Sci 20(4):901","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2150_CR156","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/hmg\/ddq430","volume":"20","author":"KJ Thomas","year":"2011","unstructured":"Thomas KJ, McCoy MK, Blackinton J et al (2011) DJ-1 acts in parallel to the PINK1\/parkin pathway to control mitochondrial function and autophagy. Hum Mol Genet 20(1):40\u201350","journal-title":"Hum Mol Genet"},{"issue":"6","key":"2150_CR157","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1476-5381.2009.00316.x","volume":"157","author":"T Tiepolo","year":"2009","unstructured":"Tiepolo T, Angelin A, Palma E et al (2009) The cyclophilin inhibitor Debio 025 normalizes mitochondrial function. Muscle apoptosis and untrastructural defects in Col6a1\u2212\/\u2212 myopathic mice. Br J Pharmacology 157(6):1045\u20131052","journal-title":"Br J Pharmacology"},{"issue":"2","key":"2150_CR158","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.expneurol.2009.03.019","volume":"218","author":"VS Van Laar","year":"2009","unstructured":"Van Laar VS, Berman SB (2009) Mitochondrial dynamics in Parkinson\u2019s disease. Exp Neurol 218(2):247\u2013256","journal-title":"Exp Neurol"},{"issue":"8","key":"2150_CR159","first-page":"a009365","volume":"12","author":"K Venderova","year":"2012","unstructured":"Venderova K, Park DS (2012) Programmed cell death in Parkinson\u2019s disease. Cold Spring Harb Perspect Med 12(8):a009365","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"2150_CR160","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1056\/NEJMoa1809983","volume":"380","author":"CVM Verschuur","year":"2019","unstructured":"Verschuur CVM, Suwijn SR, Boel JA et al (2019) Randomized delayed-start trial of levodopa in Parkinson\u2019s disease. N Engl J Med 380(4):315\u2013324","journal-title":"N Engl J Med"},{"issue":"35","key":"2150_CR161","doi-asserted-by":"crossref","first-page":"23542","DOI":"10.1074\/jbc.M801992200","volume":"283","author":"T Vogiatzi","year":"2008","unstructured":"Vogiatzi T, Xilouri M, Vekrellis S, Stefans L (2008) Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem 283(35):23542\u201323556","journal-title":"J Biol Chem"},{"issue":"3","key":"2150_CR162","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1523\/JNEUROSCI.18-03-00932.1998","volume":"18","author":"JS Wadia","year":"1998","unstructured":"Wadia JS, Chalmers-Redman RM, Ju WJ, Carlile GW, Phillips JL, Fraser AD, Tatton WG (1998) Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (\u2212)-deprenyl. J Neurosci 18(3):932\u2013947","journal-title":"J Neurosci"},{"issue":"6","key":"2150_CR163","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"J Wagner","year":"2013","unstructured":"Wagner J, Ryazonov S, Leinov A et al (2013) Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta Neuropathol 125(6):795\u2013813","journal-title":"Acta Neuropathol"},{"issue":"5","key":"2150_CR164","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1161\/STROKEAHA.108.540765","volume":"40","author":"X Wang","year":"2009","unstructured":"Wang X, Figuerosa BE, Stavrovskaya IG et al (2009) Methazolamide and melatonin inhibit mitochondrial cytochrome c release and are neuroprotective in experimental models of ischemic injury. Stroke 40(5):1877\u20131885","journal-title":"Stroke"},{"issue":"12","key":"2150_CR165","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1096\/fj.04-1916fje","volume":"18","author":"O Weinreb","year":"2004","unstructured":"Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, Youdim MB (2004) Neuroprotective via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 18(12):1471\u20131473","journal-title":"FASEB J"},{"key":"2150_CR166","first-page":"457","volume":"70","author":"O Weinreb","year":"2006","unstructured":"Weinreb O, Amit T, Bar-Am O, Sagi Y, Mandel O, Youdim MB (2006) Involvement of multiple survival signal transduction pathway in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. J Neural Transm Suppl 70:457\u2013465","journal-title":"J Neural Transm Suppl"},{"issue":"10","key":"2150_CR167","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00702-015-1398-0","volume":"122","author":"Y Wu","year":"2015","unstructured":"Wu Y, Kazumura K, Maruyama W, Osawa T, Naoi M (2015) Rasagiline and selegiline suppress calcium efflux from mitochondria by PK11195-induced opening of mitochondrial permeability transition pore: a novel antiapoptotic function for neuroprotection. J Neural Transm 122(10):1399\u20131407","journal-title":"J Neural Transm"},{"issue":"5","key":"2150_CR168","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00702-016-1531-8","volume":"123","author":"Y Wu","year":"2016","unstructured":"Wu Y, Shamoto-Nagai M, Maruyama W, Osawa T, Naoi M (2016) Rasagiline prevents cyclosporin A-sensitive superoxide flashes induced by PK11195, the initial signal of mitochondrial membrane permeabilization and apoptosis. J Neural Transm 123(5):491\u2013494","journal-title":"J Neural Transm"},{"issue":"1","key":"2150_CR169","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00702-016-1624-4","volume":"124","author":"Y Wu","year":"2017","unstructured":"Wu Y, Shamoto-Nagai M, Maruyama W, Osawa T, Naoi M (2017) Phytochemicals prevent mitochondrial membrane permeabilization and protect SH-SY5Y cells against apoptosis induced by PK11195, a ligand for outer membrane translocator protein. J Neural Transm 124(1):89\u201398","journal-title":"J Neural Transm"},{"issue":"40","key":"2150_CR170","doi-asserted-by":"crossref","first-page":"16697","DOI":"10.1074\/jbc.M117.787739","volume":"292","author":"B Xiao","year":"2017","unstructured":"Xiao B, Goh JY, Xiao L, Xian H, Lim KL, Liou YC (2017) Reactive oxygen species trigger Parkin\/PINK1 pathway-dependent mitophagy by inducing mitochondrial recruitment of Parkin. J Biol Chem 292(40):16697\u201316708","journal-title":"J Biol Chem"},{"key":"2150_CR171","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.3390\/biom5021122","volume":"5","author":"S Xu","year":"2015","unstructured":"Xu S, Chan P (2015) Interaction between neuromelanin and alpha-synuclein in Parkinson\u2019s disease. Biomolecules 5:1122\u20131142","journal-title":"Biomolecules"},{"issue":"11","key":"2150_CR172","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s00702-011-0636-3","volume":"118","author":"Q Xuan","year":"2011","unstructured":"Xuan Q, Xu SL, Lu DH, Yu S, Zhou M, Ueda K, Cui YQ, Zhang BY, Chan P (2011) Increased expression of \u03b1-synuclein in aged human brain associated with neuromelanin accumulation. J Neural Transm 118(11):1575\u20131583","journal-title":"J Neural Transm"},{"issue":"11","key":"2150_CR173","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/mds.27120","volume":"32","author":"F Yang","year":"2017","unstructured":"Yang F, Wolk A, Hakansson N, Pedersen NL, Wirdefeldt K (2017) Dietary antioxidants and risk of Parkinson\u2019s disease in two population-based cohorts. Mov Disord 32(11):1631\u20131636","journal-title":"Mov Disord"},{"key":"2150_CR174","doi-asserted-by":"crossref","first-page":"38510","DOI":"10.1038\/srep38510","volume":"6","author":"D Yedlapudi","year":"2016","unstructured":"Yedlapudi D, Joshi GS, Luo D, Todi SV, Dutta AK (2016) Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and in vivo Drosophila synucleinopathy model. Sci Rep 6:38510","journal-title":"Sci Rep"},{"issue":"1","key":"2150_CR175","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00702-005-0299-z","volume":"113","author":"H Yi","year":"2006","unstructured":"Yi H, Maruyama W, Akao Y, Takahashi T, Iwasa K, Youdim MB, Naoi M (2006) N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J Neural Transm 113(1):21\u201332","journal-title":"J Neural Transm"},{"issue":"11","key":"2150_CR176","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s00702-018-1942-9","volume":"125","author":"MBH Youdim","year":"2018","unstructured":"Youdim MBH (2018) Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases. J Neural Transm 125(11):1719\u20131733","journal-title":"J Neural Transm"},{"issue":"Suppl 1","key":"2150_CR177","doi-asserted-by":"crossref","first-page":"S287","DOI":"10.1038\/sj.bjp.0706464","volume":"147","author":"MBH Youdim","year":"2006","unstructured":"Youdim MBH, Bakhle YS (2006) Monoamine oxidase: isoforms and inhibitors in Parkinson\u2019s disease and depressive illness. Br J Pharmacol 147(Suppl 1):S287\u2013S296","journal-title":"Br J Pharmacol"},{"issue":"3","key":"2150_CR178","doi-asserted-by":"crossref","first-page":"167","DOI":"10.5607\/en.2013.22.3.167","volume":"22","author":"MBH Youdim","year":"2013","unstructured":"Youdim MBH, Oh YJ (2013) Promise of neurorestoration and mitochondrial biogenesis in Parkinson\u2019s disease with multi target drugs: an alternative to stem cell therapy. Exp Neurobiol 22(3):167\u2013172","journal-title":"Exp Neurobiol"},{"key":"2150_CR179","first-page":"57","volume":"40","author":"MB Youdim","year":"1993","unstructured":"Youdim MB, Riederer P (1993) The role of iron in senescence of dopaminergic neurons in Parkinson\u2019s disease. J Neural Transm Suppl 40:57\u201367","journal-title":"J Neural Transm Suppl"},{"issue":"11","key":"2150_CR180","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1021\/acschemneuro.7b00283","volume":"8","author":"E Zanforlin","year":"2017","unstructured":"Zanforlin E, Zagotto G, Ribaudo G (2017) The medical chemistry of natural and semisynthetic compounds against Parkinson\u2019s and Huntington\u2019s diseases. ACS Chem Neurosci 8(11):2356\u20133236","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"2150_CR181","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1161\/STROKEAHA.107.496810","volume":"39","author":"H Zhang","year":"2008","unstructured":"Zhang H, Wang H, Wang X et al (2008a) Nortriptyline protects mitochondria and reduces cerebral ischemia\/hypoxia injury. Stroke 39(2):455\u2013462","journal-title":"Stroke"},{"issue":"29","key":"2150_CR182","doi-asserted-by":"crossref","first-page":"20288","DOI":"10.1074\/jbc.M710560200","volume":"283","author":"NY Zhang","year":"2008","unstructured":"Zhang NY, Tang Z, Liu CW (2008b) \u03b1-Synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation. J Biol Chem 283(29):20288\u201320298","journal-title":"J Biol Chem"},{"issue":"8","key":"2150_CR183","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nsmb.3433","volume":"24","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Kang SS, Liu X et al (2017) Asparagine endopeptidase cleaves \u03b1-synuclein and mediates pathologic activities in Parkinson\u2019s disease. Nat Struct Mol Biol 24(8):632\u2013642","journal-title":"Nat Struct Mol Biol"},{"issue":"2","key":"2150_CR184","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1021\/acschemneuro.8b00454","volume":"10","author":"S Zhang","year":"2019","unstructured":"Zhang S, Wang R, Wang G (2019) Impact of dopamine oxidation on dopaminergic neurodegeneration. ACS Chem Neurosci 10(2):945\u2013953","journal-title":"ACS Chem Neurosci"},{"issue":"52","key":"2150_CR185","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1126\/scitranslmed.3001059","volume":"2","author":"B Zheng","year":"2010","unstructured":"Zheng B, Liao Z, Locascio JJ et al (2010) PGC-1\u03b1 potential therapeutic target for early intervention in Parkinson\u2019s disease. Sci Transl Med 2(52):52\u201373","journal-title":"Sci Transl Med"},{"issue":"4","key":"2150_CR186","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1750-3639.2003.tb00478.x","volume":"13","author":"JH Zhu","year":"2003","unstructured":"Zhu JH, Guo F, Shelburne J, Walkins S, Chu CT (2003) Localization of phosphorylated ERK\/MAP kinases to mitochondria and autophagosomes in Lewy body diseases. Brain Pathol 13(4):473\u2013481","journal-title":"Brain Pathol"},{"key":"2150_CR187","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.09.012","volume":"155","author":"FA Zucca","year":"2017","unstructured":"Zucca FA, Segura-Aguilar J, Ferrari E et al (2017) Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson\u2019s disease. Prog Neurobiol 155:96\u2013119","journal-title":"Prog Neurobiol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-020-02150-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-020-02150-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-020-02150-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T20:54:54Z","timestamp":1695675294000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-020-02150-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,28]]},"references-count":188,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["2150"],"URL":"https:\/\/doi.org\/10.1007\/s00702-020-02150-w","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,28]]},"assertion":[{"value":"12 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}